# To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

> **NCT01101321** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Reformulated OXY (Totowa) (oxycodone HCl)
- **DRUG:** Reformulated OXY (Wilson) (oxycodone HCl)

## Key facts

- **NCT ID:** NCT01101321
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-11
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2015-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101321, "To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01101321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*